Spermine Treated-Adipose Tissue-Derived Multi-Lineage Progenitor Cells Improve Left Ventricular Dysfunction in a Swine Model of Chronic Myocardial Infarction

Okura, Hanayuki; Morita, Mitsuko

doi:10.4172/2157-7633.1000326

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent advances in regenerative medicine have promised us the innovative therapeutic approaches for intractable diseases [1][2][3][4]. To move forward regenerative medicine into clinical application, some issues are here.…”

Section: Introductionmentioning

confidence: 99%

Regulatory Aspect of Pre-clinical Studies for Regenerative Medicine

Okura¹,

Matsuyama²

2016

Transl Med (sunnyvale)

Self Cite

View full text Add to dashboard Cite

Regenerative cell therapy is a discipline in youth, with only limited experience in clinical practice. Once manufacturing protocols of cells have been established in vitro studies, the manufactured cells were assigned as candidates for cell-based medicinal products. To judge whether the cell-based medicinal products manufactured according to the established protocols should be valuable for further development for clinical practice, pre-clinical studies shall be conducted. In construction of a pre-clinical study package for cell-based medicinal products, the preclinical study package used for chemical compounds will help a lot. The requirements and contents of the pre-clinical studies are classified into toxicity studies (general toxicity studies and special toxicity studies), pharmacological studies (primary pharmacodynamics studies and safety pharmacological studies), pharmacokinetic studies, formulation studies, and others. The pre-clinical studies for the cell-based medicinal products are conducted to evaluate and qualify the efficacy and safety of the candidates. No wonder there is an argument about the selection of assessment parameters in toxicity, pharmacological and pharmacokinetics studies for cell-based medicinal product, because it is well-known that the cell-based medicinal products are different in properties from chemical compounds. Besides parameters used in these studies, the assessment issues may be an assumable minimum consensus, and others should be added on a case-by-case basis, depending on the cell manufacturing processes. In anticipation of the approval as the cell-based medicinal products, the possible requirements should be discussed here in the development process of such products from the standpoint of regulatory science, especially focusing on those in pre-clinical studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Regulatory Aspect of Pre-clinical Studies for Regenerative Medicine

Okura¹,

Matsuyama²

2016

Transl Med (sunnyvale)

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among the cellular therapeutic strategies examined so far, replacement therapy had been first examined. Isolated hepatocytes or hepatic progenitor cells from human liver [11,13], regenerated hepatocyte-like or -progenitor cells from pluripotent stem cells [29,30], and in situ reprogrammable cells [9,10,31] have been tried for their efficacy in animal models. The replacement strategy has also been successful in clinical trials involving patients with certain inherited diseases [32].…”

Section: Bmentioning

confidence: 99%